{"id":"mineralocorticoid-receptor-antagonist","safety":{"commonSideEffects":[{"rate":"5–10","effect":"Hyperkalemia"},{"rate":"10–20","effect":"Gynecomastia (spironolactone)"},{"rate":"5–10","effect":"Dizziness"},{"rate":"5–10","effect":"Headache"},{"rate":"2–5","effect":"Renal impairment"}]},"_chembl":{"chemblId":"CHEMBL3642142","moleculeType":"Small molecule","molecularWeight":"422.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs competitively inhibit the mineralocorticoid receptor (MR), preventing aldosterone from binding and activating downstream pathways that promote sodium reabsorption and potassium wasting. By antagonizing MR, they promote sodium and fluid excretion while conserving potassium, leading to reduced blood volume and blood pressure. They are used primarily in heart failure, hypertension, and primary aldosteronism.","oneSentence":"Mineralocorticoid receptor antagonists block aldosterone signaling in the kidneys and other tissues, reducing sodium retention and potassium excretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:34:34.477Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction"},{"name":"Hypertension"},{"name":"Primary aldosteronism"},{"name":"Post-myocardial infarction"}]},"trialDetails":[{"nctId":"NCT07169422","phase":"NA","title":"Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2026-03-01","conditions":"Diabetic Kidney Disease, Type 2 Diabetes, Chronic Kidney Disease","enrollment":120},{"nctId":"NCT06108427","phase":"NA","title":"REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study","status":"RECRUITING","sponsor":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","startDate":"2024-04-25","conditions":"Primary Aldosteronism","enrollment":58},{"nctId":"NCT05198791","phase":"PHASE2","title":"Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.","status":"RECRUITING","sponsor":"NHS National Waiting Times Centre Board","startDate":"2022-02-04","conditions":"Myocardial Infarction, Acute, Myocardial Infarction With Nonobstructive Coronary Arteries, Myocardial Injury","enrollment":400},{"nctId":"NCT07442448","phase":"PHASE4","title":"Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure","status":"ENROLLING_BY_INVITATION","sponsor":"Cathay General Hospital","startDate":"2026-04","conditions":"Heart Failure and Preserved Ejection Fraction, Heart Failure, Heart Failure and Mildly Reduced Ejection Fraction","enrollment":40},{"nctId":"NCT07444203","phase":"","title":"Transformative Research in Diabetic Nephropathy 2.0","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-11-12","conditions":"Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic","enrollment":200},{"nctId":"NCT07167368","phase":"NA","title":"Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients","status":"RECRUITING","sponsor":"Haiyan Pan","startDate":"2025-09-15","conditions":"Cardiorenal Syndrome","enrollment":60},{"nctId":"NCT07029503","phase":"PHASE2","title":"Swedish Cardiac And Renal Failure Study-1","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2026-02","conditions":"HFrEF - Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease","enrollment":40},{"nctId":"NCT07044700","phase":"","title":"Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2028-01-31","conditions":"Heart Failure of Reduced Ejection Fraction (HFrEF)","enrollment":5000},{"nctId":"NCT06094920","phase":"PHASE4","title":"Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2024-07-29","conditions":"Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":12},{"nctId":"NCT07270172","phase":"","title":"The MICRON Study - A Steno 1 Substudy","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2025-10-27","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT04849806","phase":"","title":"Sympathetic Nerve Activity Predictors in Patients With Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"RWTH Aachen University","startDate":"2022-05-10","conditions":"COPD, Sympathetic Nervous System Diseases, Catecholamine; Overproduction","enrollment":135},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT07348718","phase":"","title":"Rubix LS Diabetic Kidney Disease (DKD) Registry Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rubix LS","startDate":"2025-12-15","conditions":"Diabetic Kidney Disease (DKD)","enrollment":2000},{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":"Severe Aortic Valve Stenosis","enrollment":25},{"nctId":"NCT07334197","phase":"NA","title":"Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-12-20","conditions":"Ppm, Cardiomyopathy","enrollment":25},{"nctId":"NCT07328230","phase":"NA","title":"Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2022-08-01","conditions":"Idiopathic Hyperaldosteronism, Hyperaldosteronism","enrollment":172},{"nctId":"NCT06029712","phase":"PHASE2","title":"Heart Failure Polypill at a Safety Net Hospital","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2024-02-27","conditions":"Heart Failure With Reduced Ejection Fraction, HIV Infections","enrollment":35},{"nctId":"NCT06185660","phase":"","title":"A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-09","conditions":"Hyperkalaemia","enrollment":125},{"nctId":"NCT02837237","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease","status":"COMPLETED","sponsor":"KBP Biosciences","startDate":"2016-07-13","conditions":"Chronic Kidney Disease","enrollment":11},{"nctId":"NCT07304817","phase":"PHASE2","title":"Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2026-02","conditions":"CKD, Cardiovascular Diseases, Heart Failure","enrollment":100},{"nctId":"NCT07295522","phase":"PHASE4","title":"Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?","status":"NOT_YET_RECRUITING","sponsor":"IRCCS Policlinico S. Donato","startDate":"2026-01-08","conditions":"Heart Failure, Acute Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)","enrollment":368},{"nctId":"NCT02653014","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment","status":"COMPLETED","sponsor":"KBP Biosciences","startDate":"2015-07-29","conditions":"Healthy, Renal Insufficiency","enrollment":26},{"nctId":"NCT05561361","phase":"","title":"The Effect of SAAE on Vascular Endothelial Function in PA Patients","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2022-10-01","conditions":"Primary Aldosteronism","enrollment":200},{"nctId":"NCT06058585","phase":"PHASE3","title":"The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-04","conditions":"Chronic Kidney Diseases","enrollment":1000},{"nctId":"NCT06818305","phase":"PHASE2","title":"Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT","status":"TERMINATED","sponsor":"Jinling Hospital, China","startDate":"2025-01-01","conditions":"Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Nephrectomy","enrollment":10},{"nctId":"NCT07262723","phase":"PHASE2, PHASE3","title":"Levosimendan in Acute Decompensated Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Chittagong Medical College","startDate":"2025-12-01","conditions":"Acute Decompensated Heart Failure (ADHF)","enrollment":332},{"nctId":"NCT04633005","phase":"PHASE2","title":"Polypill Strategy for Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-11-15","conditions":"Heart Failure","enrollment":212},{"nctId":"NCT04840342","phase":"PHASE4","title":"MR Antagonist and LSD1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-02-03","conditions":"Hypertension, Mineralocorticoid Excess","enrollment":300},{"nctId":"NCT06700213","phase":"","title":"Guideline Directed Medical Therapy in Patients With Heart Failure","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2023-09-22","conditions":"Heart Failure","enrollment":300},{"nctId":"NCT05180773","phase":"PHASE4","title":"Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy","status":"RECRUITING","sponsor":"Dennis M. McNamara, MD, MS","startDate":"2022-07-27","conditions":"Peripartum Cardiomyopathy, Postpartum","enrollment":250},{"nctId":"NCT04519164","phase":"PHASE4","title":"Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-12-01","conditions":"Metabolic Syndrome, Hypertension, Overweight and Obesity","enrollment":79},{"nctId":"NCT06381323","phase":"PHASE4","title":"The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-03-01","conditions":"Primary Aldosteronism, Finerenone, Mineralocorticoid Receptor Antagonist","enrollment":55},{"nctId":"NCT04968184","phase":"PHASE3","title":"Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)","status":"TERMINATED","sponsor":"KBP Biosciences","startDate":"2021-11-05","conditions":"Chronic Kidney Diseases","enrollment":652},{"nctId":"NCT04435626","phase":"PHASE3","title":"Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-09-14","conditions":"Heart Failure","enrollment":6016},{"nctId":"NCT05411991","phase":"PHASE4","title":"Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2022-06-12","conditions":"Acute Heart Failure, Diuretics Drug Reactions","enrollment":107},{"nctId":"NCT03476616","phase":"PHASE4","title":"Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients","status":"COMPLETED","sponsor":"Hippocration General Hospital","startDate":"2018-09-01","conditions":"Hypertension, Obesity","enrollment":198},{"nctId":"NCT05806138","phase":"PHASE2","title":"A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-07-17","conditions":"Breast Cancer, Cardiac Dysfunction","enrollment":21},{"nctId":"NCT05986695","phase":"NA","title":"Informational Nudge to Improve Heart Failure Prescribing","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-06-09","conditions":"Heart Failure","enrollment":89},{"nctId":"NCT05237323","phase":"PHASE3","title":"Micophenolate Mofetil Versus Azathioprine in Myocarditis","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2020-10-01","conditions":"Lymphocytic Myocarditis (Disorder), Heart Failure, Dilated Cardiomyopathy","enrollment":50},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT07056595","phase":"NA","title":"Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial","status":"RECRUITING","sponsor":"Botkin Hospital","startDate":"2025-05-21","conditions":"IgA Nephropathy (IgAN)","enrollment":30},{"nctId":"NCT04789239","phase":"PHASE2","title":"OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Fu","startDate":"2021-09-01","conditions":"Heart Failure, Hyperkalemia","enrollment":110},{"nctId":"NCT07026539","phase":"PHASE4","title":"Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-10-23","conditions":"Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Cardiovascular Diseases","enrollment":80},{"nctId":"NCT06906081","phase":"PHASE2","title":"Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study","status":"RECRUITING","sponsor":"Peter Rossing","startDate":"2025-05-02","conditions":"Cardiovascular Autonomic Neuropathy, Type 2 Diabetes, Diabetic Neuropathies","enrollment":100},{"nctId":"NCT05501080","phase":"NA","title":"The Effect of SAAE on Ventricular Remodeling in PA Patients","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2022-09-01","conditions":"Primary Aldosteronism","enrollment":112},{"nctId":"NCT03833089","phase":"PHASE4","title":"Targeted Potassium Levels for Prevention of ICD Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2019-03-01","conditions":"Ventricular Arrhythmias and Cardiac Arrest, Implantable Defibrillator User, Hypokalemia","enrollment":1200},{"nctId":"NCT05797558","phase":"NA","title":"Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment","status":"RECRUITING","sponsor":"Göteborg University","startDate":"2023-04-28","conditions":"Primary Hyperaldosteronism Due to Adrenal Adenoma","enrollment":80},{"nctId":"NCT03683069","phase":"PHASE4","title":"Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-01-15","conditions":"Hypertension, Genetics Hypertension","enrollment":90},{"nctId":"NCT05021419","phase":"NA","title":"Efficacy of a Streamlined Heart Failure Optimization Protocol","status":"COMPLETED","sponsor":"The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust","startDate":"2022-07-17","conditions":"Heart Failure with Reduced Ejection Fraction, Chronic Heart Failure","enrollment":60},{"nctId":"NCT06033950","phase":"PHASE3","title":"A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists","status":"RECRUITING","sponsor":"Colorado Prevention Center","startDate":"2024-08-20","conditions":"Heart Failure","enrollment":2600},{"nctId":"NCT05933265","phase":"PHASE1, PHASE2","title":"Study of LP-184 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Lantern Pharma Inc.","startDate":"2023-06-09","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, GBM","enrollment":175},{"nctId":"NCT06727409","phase":"PHASE4","title":"Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-12-12","conditions":"Patients With Type 2 Diabetes","enrollment":82},{"nctId":"NCT06655480","phase":"PHASE2","title":"Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF","status":"NOT_YET_RECRUITING","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2025-03-18","conditions":"HFpEF, LVDD, Myocardial Fibrosis","enrollment":50},{"nctId":"NCT05030545","phase":"PHASE4","title":"Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-12-15","conditions":"Primary Aldosteronism, Hypertension","enrollment":40},{"nctId":"NCT04768322","phase":"NA","title":"LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2021-02-24","conditions":"End-stage Heart Failure","enrollment":92},{"nctId":"NCT05129722","phase":"PHASE4","title":"Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial","status":"TERMINATED","sponsor":"The George Institute","startDate":"2022-10-01","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":3},{"nctId":"NCT06637618","phase":"NA","title":"Does the Sequence of Heart Failure Medication Matter","status":"NOT_YET_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-02-01","conditions":"Heart Failure, Reduced Ejection Fraction","enrollment":16000},{"nctId":"NCT05526157","phase":"","title":"An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-10-01","conditions":"Chronic Kidney Disease, Type 2 Diabetes Mellitus","enrollment":50000},{"nctId":"NCT05275920","phase":"NA","title":"Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure (BETTER CARE-HF)","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2022-04-28","conditions":"Heart Failure, Heart Failure With Reduced Ejection Fraction","enrollment":2211},{"nctId":"NCT06629246","phase":"NA","title":"Pogejiuxin Decoction Combination of Conventional Western Medicine for the Treatment of Heart Failure with Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Chongqing Traditional Chinese Medicine Hospital","startDate":"2021-09-01","conditions":"Heart Failure, Diastolic (HFpEF)","enrollment":100},{"nctId":"NCT05824923","phase":"PHASE3","title":"A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure","status":"RECRUITING","sponsor":"Pulnovo Medical (Wuxi) Co., Ltd.","startDate":"2023-08-14","conditions":"Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension","enrollment":264},{"nctId":"NCT05419583","phase":"NA","title":"Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2022-11-14","conditions":"Myocardial Infarction Type 2","enrollment":60},{"nctId":"NCT06091475","phase":"NA","title":"Therapy to Maintain Remission in Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2023-12-02","conditions":"Heart Failure, Cardiomyopathy, Dilated, Cardiomyopathies","enrollment":50},{"nctId":"NCT04903717","phase":"NA","title":"Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-11-03","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":1210},{"nctId":"NCT05364190","phase":"PHASE3","title":"Canagliflozin in Patients With Acute Decompansted Heart Failure","status":"COMPLETED","sponsor":"October 6 University","startDate":"2022-06-04","conditions":"Chronic Heart Failure, Acute Heart Failure, Diabetes Mellitus","enrollment":142},{"nctId":"NCT05623358","phase":"NA","title":"PHARM Optimal-HF Pilot","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2023-03-13","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":42},{"nctId":"NCT03344159","phase":"PHASE4","title":"Spironolactone Therapy in Chronic Stable Right HF Trial","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2018-04-01","conditions":"Chronic Right-Sided Heart Failure, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Primary, 2","enrollment":15},{"nctId":"NCT04556279","phase":"","title":"Investigating Salt Taste Threshold in Patients Being Investigated for Primary Hyperaldosteronism Before and After Treatment.","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2021-01","conditions":"Hyperaldosteronism; Primary, Hypertension, Salt; Excess","enrollment":""},{"nctId":"NCT05806970","phase":"NA","title":"Email Nudges to Improve GDMT (MRA) Adherence in Heart Failure","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-04","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":""},{"nctId":"NCT01563731","phase":"PHASE4","title":"Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2013-04","conditions":"Stroke, Transient Ischemic Attack, Hypertension","enrollment":200},{"nctId":"NCT06201000","phase":"","title":"Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients","status":"UNKNOWN","sponsor":"October 6 University","startDate":"2023-12-27","conditions":"Genetic Polymorphisms, Heart Failure","enrollment":282},{"nctId":"NCT02351063","phase":"NA","title":"HF Assessment With BNP in the Home: Part II","status":"TERMINATED","sponsor":"Alere San Diego","startDate":"2014-04","conditions":"Heart Failure","enrollment":1},{"nctId":"NCT06175663","phase":"","title":"Hyperintense: Midlife Hypertension and the Brain","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2021-07-06","conditions":"Hypertension, Small Vessel Cerebrovascular Disease","enrollment":130},{"nctId":"NCT05407662","phase":"","title":"A Study Using Surveys to Learn More About Treatment With Steroidal Mineralocorticoid Receptor Antagonists, How They Are Used, What Side Effects They Have, and How Satisfied People Who Receive Them Are in the US","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-11-02","conditions":"Chronic Kidney Disease, Type 2 Diabetes Mellitus, Heart Failure","enrollment":600},{"nctId":"NCT05212649","phase":"","title":"Optimized Peak VO2 in Predicting Advanced HF","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2014-05-01","conditions":"Heart Failure, Morality, Transplant; Failure, Heart","enrollment":377},{"nctId":"NCT04588688","phase":"PHASE2","title":"Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency","status":"TERMINATED","sponsor":"Tobias Else","startDate":"2021-05-05","conditions":"Central Adrenal Insufficiency, Mifepristone","enrollment":3},{"nctId":"NCT02740179","phase":"NA","title":"Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-01","conditions":"HIV","enrollment":40},{"nctId":"NCT05873400","phase":"","title":"Effect of Renin Angiotensin Aldosterone System Genetic Polymorphism on the Pharmacological Effect of Mineralocorticoid Receptor Antagonists in Patients With Myocardial Infarction","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-08-01","conditions":"Myocardial Infarction","enrollment":102},{"nctId":"NCT05865665","phase":"","title":"Registry Of Best Up-titration STrategies in Acute Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Heart Initiative","startDate":"2023-06","conditions":"Acute Heart Failure","enrollment":5000},{"nctId":"NCT02592499","phase":"NA","title":"Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2016-06","conditions":"End-stage Heart Failure","enrollment":80},{"nctId":"NCT05814770","phase":"PHASE4","title":"Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-05","conditions":"Primary Aldosteronism, Hypertension","enrollment":96},{"nctId":"NCT05688579","phase":"PHASE4","title":"Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia","status":"ENROLLING_BY_INVITATION","sponsor":"Nanfang Li","startDate":"2023-04-16","conditions":"Hypertension, Hyperaldosteronaemia","enrollment":8000},{"nctId":"NCT05663372","phase":"PHASE1","title":"Bioequivalence Study of Test and Reference 50 mg Eplerenone Film-coated Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Darnitsa Pharmaceutical Company","startDate":"2021-12-07","conditions":"Bioequivalence, Healthy Subjects","enrollment":36},{"nctId":"NCT02497300","phase":"PHASE2","title":"Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2015-03","conditions":"Chronic Kidney Disease, Albuminuria","enrollment":21},{"nctId":"NCT05077293","phase":"","title":"Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-09-09","conditions":"Heart Failure, Heart Failure With Reduced Ejection Fraction","enrollment":596},{"nctId":"NCT03789357","phase":"","title":"Prevalence of Primary Aldosteronism in Patients With Stroke","status":"COMPLETED","sponsor":"Changi General Hospital","startDate":"2018-05-01","conditions":"Primary Aldosteronism, Stroke","enrollment":300},{"nctId":"NCT03174847","phase":"","title":"Prospective Study Assessing Blood Pressure and Other Outcomes Post-treatment in Patients With Primary Aldosteronism","status":"COMPLETED","sponsor":"Changi General Hospital","startDate":"2017-02-20","conditions":"Primary Aldosteronism, Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)","enrollment":57},{"nctId":"NCT04697485","phase":"PHASE4","title":"Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2021-01-08","conditions":"HF - Heart Failure, Diabetes Mellitus","enrollment":""},{"nctId":"NCT02556450","phase":"PHASE2","title":"Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure","status":"COMPLETED","sponsor":"ACS Biomarker","startDate":"2016-01","conditions":"Heart Failure","enrollment":528},{"nctId":"NCT05262660","phase":"","title":"The Long-term Effect of SAAE and Medical Treatment for Primary Aldosteronism","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chengdu Medical College","startDate":"2022-04-01","conditions":"Primary Aldosteronism","enrollment":400},{"nctId":"NCT04217135","phase":"PHASE4","title":"The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation","status":"UNKNOWN","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2017-01-01","conditions":"Systolic Heart Failure Stage D (Disorder), Mitral Regurgitation","enrollment":400},{"nctId":"NCT05090137","phase":"NA","title":"Quantifying Congestion by Ultrasound","status":"UNKNOWN","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2021-11","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT05045274","phase":"NA","title":"The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-12","conditions":"STEMI - ST Elevation Myocardial Infarction, Left Ventricular Systolic Dysfunction","enrollment":300},{"nctId":"NCT00877643","phase":"NA","title":"Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure","status":"COMPLETED","sponsor":"I.C. Van Gelder","startDate":"2009-05-04","conditions":"Atrial Fibrillation","enrollment":250},{"nctId":"NCT04428827","phase":"","title":"Outcome of Patients With Primary Aldosteronism","status":"UNKNOWN","sponsor":"Changi General Hospital","startDate":"2016-10-01","conditions":"Primary Aldosteronism, Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)","enrollment":600},{"nctId":"NCT04575675","phase":"PHASE4","title":"Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy","status":"COMPLETED","sponsor":"Cheng-Hsin General Hospital","startDate":"2020-05-29","conditions":"Hypotension, Heart Failure","enrollment":78},{"nctId":"NCT04912011","phase":"PHASE4","title":"Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.","status":"UNKNOWN","sponsor":"Pomeranian Medical University Szczecin","startDate":"2021-01-01","conditions":"COVID-19 Pneumonia","enrollment":50},{"nctId":"NCT03071653","phase":"PHASE2","title":"Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study","status":"SUSPENDED","sponsor":"University of Cape Town","startDate":"2016-11-24","conditions":"Dilated Cardiomyopathy, Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy","enrollment":30},{"nctId":"NCT02362308","phase":"","title":"Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2015-01","conditions":"Primary Aldosteronism","enrollment":10},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"INTENTIONAL DOSE OMISSION"},{"count":1,"reaction":"LOW CARDIAC OUTPUT SYNDROME"},{"count":1,"reaction":"MULTIPLE ORGAN DYSFUNCTION SYNDROME"},{"count":1,"reaction":"OBESITY"}],"_approvalHistory":[],"publicationCount":1582,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aldactin, Inspra","spironolactone","eplerenone"],"phase":"marketed","status":"active","brandName":"Mineralocorticoid Receptor Antagonist","genericName":"Mineralocorticoid Receptor Antagonist","companyName":"Cheng-Hsin General Hospital","companyId":"cheng-hsin-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mineralocorticoid receptor antagonists block aldosterone signaling in the kidneys and other tissues, reducing sodium retention and potassium excretion. Used for Heart failure with reduced ejection fraction, Hypertension, Primary aldosteronism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}